Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-LVO: Intra-arterial Methylprednisolone After Thrombectomy for Stroke
NCT07516522Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Methylprednisolone sodium succinate with Placebo (2 arms). Primary endpoints: Incidence of symptomatic intracranial hemorrhage at 48 hours and Mortality at 90 days. Started Mar 2026; status: recruiting.
02
Drugs
methylprednisolone sodium succinate
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07516522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516522.